Prevalence and genetic diversity of enteric viruses in Sub-Saharan Africa: a systematic review and meta-analysis
Abstract
Rotavirus A (RVA), norovirus (NoV), human astrovirus (HAstV), and sapovirus (SaV) are the main viruses responsible for acute gastroenteritis worldwide. Among them, RVA is generally the most prevalent, predominantly in Sub-Saharan Africa. With the introduction of RVA vaccines, several epidemiological changes have been reported in cases of viral gastroenteritis, particularly in Sub-Saharan Africa. Therefore, it is essential to understand the current burden and diversity of these viruses in order to guide public health interventions and vaccination strategies in the region. Our objective was to examine changes in prevalence data and circulating genotypes of RVA, NoV, SaV, and HAstV associated with acute gastrointestinal infections in both adults and children in Sub-Saharan Africa, based on studies published between 2010 and 2023. A systematic search was conducted in PubMed and Google Scholar to identify relevant studies published between 2010 and 2023, focusing exclusively on Sub-Saharan Africa. No restrictions were applied in terms of language or age group. Study selection, data extraction, and methodological quality assessment were performed using standardized procedures. Heterogeneity between studies was assessed using Cochrane’s Q test and the I² statistic in a random-effects model. Combined prevalence estimates for RVA, NoV, SaV, and HAstV were calculated using Comprehensive Meta-Analysis software. A total of 55 studies from 19 countries in Sub-Saharan Africa were…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.